Data Presented at ENDO 2021 Differentiate LUM-201 from General Growth Hormone Secretagogues and Additional Support LUM-201’s Potential as Therapeutic for Pediatric Growth Hormone Deficiency Nasdaq: LUMO

AUSTIN, Texas, March 20, 2021 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-grade biopharmaceutical company dedicated to medical treatment for rare diseases, poster 7102 with the title, “LUM-201 Has a Larger GH Response than General GH Secretagogues in Pediatric Growth Hormone Deficiency, ” presented by the authors Bright, G., et al in Poster Session 33 at ENDO 2021, Annual Meeting of the Endocrine Society, taking place almost from March 20-23, 2021. The poster can be viewed on the ENDO website and can also be viewed on the Company’s website there in the Investors & Media section, under “Posters & Publications.”

“These data presented today at the Annual Meeting of the Endocrine Association highlight the unique ability of LUM-201 to stimulate higher GH levels significantly higher than those produced by conventional GH secrets. , ”Said John McKew, PhD, Chief Operating Officer and Chief Scientific Officer of Lumos Pharma. “Along with previously published data by Nass, et al showing the effect of 24-hour PD measured by GH release in adults taking LUM-201 shows that LUM-201 is very different from other secrets in terms of its ability to be used effectively. therapeutic. These results support data analyzes by Bright, et al and Blum, et al recently published in the Journal of the Endocrine Society demonstrates the ability of LUM-201 to have a therapeutic response in pediatric patients with moderate growth hormone deficiency, or 60% of the total PGHD population, as indicated by our specific predictive enrichment symptoms and increased confidence give us in potential LUM efficiency. -201 in this patient population. “

Poster 7102 provides an analysis of data from a preliminary clinical study comparing the maximum growth hormone (GH) response of LUM-201 (formerly MK-0677) with the response of normal GH secretions (clonidine, arginine , L-dopa, glucagon, insulin) in naïve-to-treatment children, previously diagnosed with growth hormone deficiency (GHD). The goal was to determine whether LUM-201 stimulates different GH responses from normal GH secretagogues. In this study, 68 oral prepubertal children with GHD were given a single oral dose of 0.8 mg / kg of LUM-201 with a median baseline age of 9.2 years, SDS height of -3.3, preoperative height (HV) of 4.0 cm / yr, and an IGF-1 baseline of 51 ng / mL. The results showed a maximum median GH response to a single oral LUM-201 dose of 15.0 ng / mL, a statistically significant difference compared to a peak response of 5.4 ng / mL GH to different pairs of standard GH stimulation tests. (p <0.00001). In a multivariate study (r2 = 0.73) differentiated GH increased with higher baseline values ​​of IGF-1 (p <0.00001) and normal GH stimulation test (p = 0.047) but no effect on age (p = 0.16), gender (p = 0.28), baseline HV (p = 0.24), bone-age differences (p = 0.33) or SDS-height (p = 0.75).

The analysis shows that, in children with GHD, GH response to a single oral dose of LUM-201 is significantly higher than that observed with normal GH stimulant agents. The difference in GH responses increases with higher baseline concentrations of IGF-1 and higher GH stimulation test results. The synergistic actions of LUM-201 on the psychosocial mechanisms that regulate GH release explain why GH responses are greater in response to LUM-201 compared to traditional experiments used for Determining PGHD and showing that the greatest differences are found in children with more moderate levels of GHD.

Mu Lumos Pharma

Lumos Pharma, Inc. is a clinical-grade biopharmaceutical company with a focus on the development and commercialization of pharmaceuticals for rare diseases. Lumos Pharma was founded and led by a management team with long-term experience in the development of rare disease drugs and received early funding from major healthcare investors, including Deerfield Management, a fund funded by managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. The main therapeutic candidate is Lumos Pharma LUM-201, a small molecular-stimulating oral growth hormone, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Test, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that routine PGHD patients endure for several years of treatment. LUM-201 has received orphan drug designation in the US and the EU. For more information, visit

Warning note for forward-looking statements

This press release contains positive statements about Lumos Pharma, Inc. (the “Company”) in which there are significant risks and uncertainties. All of these statements in this press release are forward-looking statements within the meaning of the Private Security Literature Reform Act 1995. The words “forecast,” “projected,” “direction , ”“ Forthcoming, ”“ yes, ”“ would, ”“ Plan, ”“ expect, ”“ expect, ”“ approximate, ”“ expect, ”“ ability, ”“ imminent, ”or negative of the terms this or other similar phrases are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, plans related to the performance of clinical trials, and any other statements in addition to historical fact statements. Actual results or events may differ materially from the plans, intentions and expectations disclosed in the Company’s forward-looking statements due to a number of material factors, including the impact of pandemics or other widespread health problems such as the chronic COVID-19 pandemic, the outcome of our future interactions with regulatory authorities, the outcome of our OraGrowtH210 Level 2b Test for LUM-201, our ability to use money in the plan the future and resources needed for future contingent responsibilities and business operations, access to adequate resources for our operations and to conduct or pursue planned clinical improvement programs, the ability to obtain the necessary patient registration for our product candidate in a timely manner, the ability to successfully develop our product candidate, the associated risks to the development process, obtaining regulatory approval for and trading on drug candidates such as LUM-201 that are safe and effective for use as human medicine, time and capacity of Lumos to raise additional equity capital as required and other risks that may cause actual results to differ materially from those issues that are exacerbated or identified by forward-looking statements as reported. discussed in “Danger. Factors “and elsewhere in the Company’s Annual Report on Form 10-K for the year to December 31, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent views from the date of this press release The Company expects subsequent events and developments to change its views, however, although it may choose to update these forward-looking statements at some point in the future. in the future, the Company expressly disclaims any responsibility for doing so, so you should not rely on these forward-looking statements as a representation of the Company’s views as of any date. after the date of this press release.

Contact investor & media:

Lisa Miller
Lumos Pharma investor relationship
[email protected]